TRAF3IP2 and glioblastoma: Consistent with its role in modulating both immunity and angiogenesis (48), our data show that targeting TRAF3IP2 downregulates PGF expression and signaling (Figure 4), suggesting that targeting TRAF3IP2 potentially suppresses both angiogenesis and immune suppression in GBM.